(Q37799352)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Cost effectiveness of pharmacogenomics: a critical and systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

cost-effectiveness analysis

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Josh J Carlson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Rahber Thariani

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

David L Veenstra

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

1001-1013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20936884%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11537410-000000000-00000

15 February 2020

exact match

0 references

cites work

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537410-000000000-00000

Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

12 December 2020

Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms.

1 reference

12 December 2020

Genomic and personalized medicine: foundations and applications

1 reference

12 December 2020

MRPS18CP2 alleles and DEFA3 absence as putative chromosome 8p23.1 modifiers of hearing loss due to mtDNA mutation A1555G in the 12S rRNA gene

1 reference

12 December 2020

The role of cost-effectiveness analysis in the era of pharmacogenomics

1 reference

12 December 2020

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model

1 reference

12 December 2020

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.

1 reference

12 December 2020

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

1 reference

12 December 2020

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin

1 reference

12 December 2020

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis

1 reference

12 December 2020

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

1 reference

12 December 2020

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

1 reference

12 December 2020

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

1 reference

12 December 2020

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines

1 reference

12 December 2020

Personalized medicine and inhibition of EGFR signaling in lung cancer

1 reference

12 December 2020

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

12 December 2020

Examining the value and quality of health economic analyses: implications of utilizing the QHES.

1 reference

12 December 2020

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

1 reference

12 December 2020

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.

1 reference

12 December 2020

Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases

1 reference

12 December 2020

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

1 reference

12 December 2020

Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands

1 reference

12 December 2020

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis

1 reference

12 December 2020

Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review

1 reference

12 December 2020

Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

12 December 2020

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study

1 reference

12 December 2020

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

1 reference

12 December 2020

Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case

1 reference

12 December 2020

Economic analyses of human genetics services: a systematic review

1 reference

12 December 2020

Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic Fever.

1 reference

12 December 2020

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

12 December 2020

Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis

1 reference

12 December 2020

Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data

1 reference

12 December 2020

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

1 reference

12 December 2020

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

1 reference

12 December 2020

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

1 reference

12 December 2020

Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France

1 reference

12 December 2020

Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate.

1 reference

12 December 2020

Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

1 reference

12 December 2020

Cost implications of specialized coagulation testing for acute ischemic stroke

1 reference

12 December 2020

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

1 reference

12 December 2020

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

1 reference

12 December 2020

Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer

1 reference

12 December 2020

The cost-effectiveness of interleukin-1 genetic testing for periodontal disease

1 reference

12 December 2020

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

1 reference

12 December 2020

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis

1 reference

12 December 2020

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

1 reference

12 December 2020

Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease.

1 reference

12 December 2020

Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147

1 reference

12 December 2020

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

1 reference

12 December 2020

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis

1 reference

12 December 2020

Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine

1 reference

12 December 2020

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

12 December 2020

Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes

1 reference

12 December 2020

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

1 reference

12 December 2020

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

12 December 2020

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.

1 reference

12 December 2020

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

1 reference

12 December 2020

Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.

1 reference

12 December 2020

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

1 reference

12 December 2020

Pharmacogenetic testing in psychiatry: a review of features and clinical realities.

1 reference

12 December 2020

Overview of the pharmacoeconomics of pharmacogenetics

1 reference

12 December 2020

Development and validation of a grading system for the quality of cost-effectiveness studies

1 reference

12 December 2020

Warfarin and pharmacogenomic testing: the case for restraint

1 reference

12 December 2020

Screening for factor V Leiden mutation before prescribing combination oral contraceptives

1 reference

12 December 2020

Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands

1 reference

12 December 2020

Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer

1 reference

12 December 2020

Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.

1 reference

12 December 2020

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

1 reference

12 December 2020

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

1 reference

12 December 2020

A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation

1 reference

12 December 2020

Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.

1 reference

12 December 2020

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

1 reference

12 December 2020

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease

1 reference

12 December 2020